Clinical Report: Patterns of Medication Discontinuation and Their Impact
Background
Medication shortages pose significant challenges to healthcare systems, impacting patient care and safety. In Brazil, the management of drug discontinuations is primarily reactive, relying on a single panel to monitor interruptions in manufacturing. Understanding the patterns and reasons for these discontinuations is crucial for ensuring access to essential medicines.
Data Highlights
This study utilized a quantitative, observational design analyzing data from ANVISA’s medicine-discontinuation panel for the years 2014 to 2024.
Key Findings
Drug shortages are defined by the WHO from both supply and demand perspectives.
Brazil's approach to managing medication discontinuations is largely reactive, focusing on monitoring rather than preventing shortages.
ANVISA mandates that manufacturers report any discontinuation of production or importation.
Countries like Israel and Canada have implemented proactive measures to address drug shortages, contrasting with Brazil's current strategies.
Clinical Implications
Healthcare providers should be aware of the potential for medication shortages and the impact on patient treatment plans. Enhanced monitoring and proactive strategies may be necessary to mitigate the risks associated with drug discontinuations.
Conclusion
The study highlights the critical need for a comprehensive approach to managing medication discontinuations in Brazil to ensure the availability of essential medicines.
by Raphaella Oliveira Martins de Lima, Esther Ramos Silva, Isabel C. M. Emmerick, Danielle Maria de Souza Serio dos Santos, Isabella Piassi Dias Godói, Ana Cristina Viana Campos, Luisa Arueira Chaves
